Biocon Ltd

Biocon Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Biocon Ltd

₹ 240 -2.06%
02 Jun - close price
biocon.com BSE: 532523 NSE : BIOCON
About

Biocon is engaged in the business of manufacture of biotechnology products and research services.(Source : 202003-01 Annual Report Page No:195)

Key Points

Biologics (41%)[1]
Has one of the largest biosimilar pipelines comprising 28 molecules to be launched over the next decade. [2]

It is among the world’s Top 15 bio-manufacturing companies. Only Indian company to get FDA approval for 3 biosimilar molecules (Trastuzumab, Pegfilgrastim, and Insulin Glargine) [3]

The historic approval of the world’s first interchangeable biosimila-bGlargine, in the U.S. was the key highlight of FY22. [4]

Website BSE NSE
  • Market Cap ₹ 28,844 Cr.
  • Current Price ₹ 240
  • High / Low ₹ 344 / 192
  • Stock P/E 47.0
  • Book Value ₹ 149
  • Dividend Yield 0.62 %
  • ROCE 6.50 %
  • ROE 4.66 %
  • Face Value ₹ 5.00
Edit ratios

Pros

  • Company is expected to give good quarter

Cons

  • Company has a low return on equity of 7.26% over last 3 years.
  • Company might be capitalizing the interest cost
  • Debtor days have increased from 95.1 to 117 days.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Mar 2020 Jun 2020 Sep 2020 Dec 2020 Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023
1,558 1,694 1,750 1,857 1,842 1,761 1,840 2,174 2,409 2,140 2,320 2,941 3,774
1,247 1,284 1,363 1,459 1,476 1,427 1,445 1,733 1,870 1,783 1,877 2,352 2,817
Operating Profit 310 410 386 399 366 333 395 441 539 356 442 589 957
OPM % 20% 24% 22% 21% 20% 19% 21% 20% 22% 17% 19% 20% 25%
63 18 16 28 218 47 35 48 26 78 48 -193 152
Interest 17 12 6 5 34 20 22 15 10 20 30 120 249
Depreciation 152 167 178 186 184 195 202 206 212 218 231 301 364
Profit before tax 204 249 218 236 366 166 206 269 342 197 229 -26 497
Tax % 22% 33% 10% 21% 19% 35% 22% 18% 17% 15% 64% 19% 17%
Net Profit 159 168 195 187 296 108 160 220 284 167 82 -21 414
EPS in Rs 1.03 1.24 1.41 1.40 2.11 0.70 1.15 1.56 1.99 1.20 0.39 -0.35 2.61
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
2,086 2,485 2,877 3,090 3,347 3,891 4,123 5,514 6,300 7,143 8,184 11,174
1,569 1,942 2,190 2,394 2,957 2,912 3,294 4,121 4,725 5,562 6,418 8,830
Operating Profit 517 543 687 696 390 980 829 1,394 1,575 1,581 1,766 2,345
OPM % 25% 22% 24% 23% 12% 25% 20% 25% 25% 22% 22% 21%
62 255 56 158 639 173 228 340 228 260 99 84
Interest 12 8 2 9 29 26 62 71 65 58 68 419
Depreciation 174 179 204 221 249 277 385 448 552 715 814 1,113
Profit before tax 392 610 538 624 751 850 610 1,215 1,186 1,068 983 897
Tax % 14% 16% 20% 15% 19% 19% 26% 17% 27% 21% 22% 28%
Net Profit 338 513 431 528 609 688 453 1,003 871 846 772 643
EPS in Rs 2.82 4.24 3.45 4.14 4.59 5.10 3.10 7.54 6.24 6.17 5.40 3.85
Dividend Payout % 30% 29% 24% 20% 18% 10% 16% 7% 0% 0% 9% 39%
Compounded Sales Growth
10 Years: 16%
5 Years: 22%
3 Years: 21%
TTM: 37%
Compounded Profit Growth
10 Years: 6%
5 Years: 13%
3 Years: -4%
TTM: -14%
Stock Price CAGR
10 Years: 18%
5 Years: -5%
3 Years: -15%
1 Year: -25%
Return on Equity
10 Years: 9%
5 Years: 9%
3 Years: 7%
Last Year: 5%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
100 100 100 100 100 100 300 300 600 600 600 600
Reserves 2,172 2,595 2,927 3,171 3,934 4,738 4,881 5,798 6,106 7,027 7,832 17,267
271 267 864 1,117 2,478 2,302 2,264 2,422 2,715 4,481 5,147 18,019
1,402 1,454 1,860 1,988 1,947 2,254 2,545 3,672 4,993 6,382 6,763 16,157
Total Liabilities 3,945 4,416 5,751 6,375 8,458 9,394 9,990 12,192 14,414 18,490 20,342 52,043
1,270 1,510 1,525 1,630 1,748 3,626 3,700 4,471 5,971 6,364 6,569 34,197
CWIP 390 312 1,206 1,677 2,240 839 1,303 1,899 2,196 2,800 4,110 2,588
Investments 556 587 765 230 902 1,253 675 1,012 966 1,952 1,588 2,069
1,729 2,007 2,255 2,839 3,569 3,676 4,312 4,811 5,281 7,374 8,074 13,189
Total Assets 3,945 4,416 5,751 6,375 8,458 9,394 9,990 12,192 14,414 18,490 20,342 52,043

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
594 471 561 211 371 640 662 1,155 1,283 1,160 1,177 1,852
-398 -358 -904 -491 -1,138 -510 -684 -703 -1,505 -3,651 -1,662 -14,282
-186 -9 426 186 1,068 -178 -240 -242 388 2,564 242 13,049
Net Cash Flow 10 105 83 -94 300 -47 -261 210 165 72 -243 619

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Debtor Days 86 75 76 91 78 83 94 86 71 77 92 117
Inventory Days 162 139 116 132 153 160 161 199 263 304 309 423
Days Payable 149 121 107 125 172 187 224 231 243 246 216 397
Cash Conversion Cycle 99 93 85 98 59 57 31 53 91 134 184 143
Working Capital Days 27 21 -0 12 31 34 18 15 8 80 112 129
ROCE % 16% 15% 16% 13% 9% 13% 8% 13% 13% 10% 9% 6%

Shareholding Pattern

Numbers in percentages

5 Recently
Jun 2020 Sep 2020 Dec 2020 Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023
60.67 60.67 60.67 60.67 60.64 60.64 60.64 60.64 60.64 60.64 60.64 60.64
15.93 16.69 17.65 16.30 15.91 15.74 16.00 15.62 16.31 15.79 14.42 10.20
7.18 6.29 6.03 7.14 7.52 7.44 7.37 8.36 7.72 7.76 8.63 11.89
15.08 15.33 14.67 14.96 15.02 15.46 15.34 14.76 14.60 15.17 15.74 16.70
1.13 1.02 0.98 0.93 0.91 0.72 0.65 0.63 0.73 0.63 0.58 0.55

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

DRHP

Credit ratings

Concalls